← 返回

用于免疫组库分析及分离肿瘤反应性 TCR 的 TCR 测序与克隆方法

英文原题:TCR sequencing and cloning methods for repertoire analysis and isolation of tumor-reactive TCRs.

查看英文原题

TCR sequencing and cloning methods for repertoire analysis and isolation of tumor-reactive TCRs.

PubMed 2023/04/24(内容时间) Cell Rep Methods Q1 · IF 5.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

T 细胞受体(TCR)技术,包括免疫组库分析和 T 细胞工程,在癌症、移植和其他免疫疾病的细胞免疫临床管理中日益重要。然而,用于免疫组库分析和 TCR 克隆的灵敏可靠方法仍然缺乏。在此,我们报告了 SEQTR,一种分析人类和小鼠免疫组库的高通量方法,与常用检测方法相比,它更灵敏、可重复且准确,因此能更可靠地捕捉血液和肿瘤 TCR 免疫组库的复杂性。我们还提出了一种 TCR 克隆策略,可从 T 细胞群体中特异性扩增 TCR。该策略位于单细胞或批量 TCR 测序的下游,能够以省时且经济高效的方式发现、克隆、筛选和改造肿瘤特异性 TCR。总之,这些方法将加速在发现、转化和临床环境中的 TCR 免疫组库分析,并为细胞疗法实现快速 TCR 工程化。

展开英文摘要原文

T cell receptor (TCR) technologies, including repertoire analyses and T cell engineering, are increasingly important in the clinical management of cellular immunity in cancer, transplantation, and other immune diseases.

However, sensitive and reliable methods for repertoire analyses and TCR cloning are still lacking.

Here, we report on SEQTR, a high-throughput approach to analyze human and mouse repertoires that is more sensitive, reproducible, and accurate as compared with commonly used assays, and thus more reliably captures the complexity of blood and tumor TCR repertoires.

We also present a TCR cloning strategy to specifically amplify TCRs from T cell populations. Positioned downstream of single-cell or bulk TCR sequencing, it allows time- and cost-effective discovery, cloning, screening, and engineering of tumor-specific TCRs.

Together, these methods will accelerate TCR repertoire analyses in discovery, translational, and clinical settings and permit fast TCR engineering for cellular therapies.

论文信息

作者
Genolet R、Bobisse S、Chiffelle J、Arnaud M、Petremand R、Queiroz L、Michel A、Reichenbach P
单位
Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne and Lausanne University Hospital, Lausanne, Switzerland.Switzerland
文献类型
非美国政府资助研究
期刊
Cell reports methods2023 Apr 24
原文标识
PubMed 37159666 · DOI 10.1016/j.crmeth.2023.100459